Modulators of angiogenesis
View Patent ↗The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
1. A method for identifying a compound that inhibits angiogenesis, the method comprising the steps of:
(i) contacting human ubiquitin hydrolase specific protease 37 (USP37) polypeptide with the compound,
(ii) measuring USP37 polypeptide for ubiquitin hydrolase activity in the presence of the compound, wherein the USP37 polypeptide has ubiquitin hydrolase activity in the absence of the compound,
(iii) contacting an endothelial cell with said compound identified in step (ii),
(iv) measuring a change in angiogenesis phenotype in the endothelial cell by measuring VEGF-R2 surface expression, ανβ5 integrin expression, endothelial cell tube formation or haptotaxis in the presence of said compound
wherein inhibition of ubiquitin hydrolase activity in the presence of said compound as compared with activity in the absence of said compound, and reduction in VEGF-R2 surface expression, ανβ5 integrin expression, endothelial cell tube formation or haptotaxis, identifies said compound as a compound that inhibits angiogenesis.
2. The method of claim 1 , wherein the angiogenesis phenotype is determined in vitro.
3. The method of claim 1 , wherein the USP37 polypeptide is recombinant.
4. The method of claim 1 , wherein the compound is an antibody.
5. The method of claim 1 , wherein the compound is an antisense molecule.
6. The method of claim 1 , wherein the compound is an RNAi molecule.
7. The method of claim 1 , wherein the compound is a small organic molecule.
8. A method for identifying a compound that inhibits angiogenesis, the method comprising:
contacting the compound with an endothelial cell comprising a recombinant human ubiquitin hydrolase specific protease 37 (USP37) polypeptide, wherein the recombinant human USP37 polypeptide has ubiquitin hydrolase activity; and
measuring a change in angiogenesis phenotype in the endothelial cell by measuring VEGF-R2 surface expression, ανβ5 integrin expression, endothelial cell tube formation or haptotaxis in the presence of said compound,
wherein reduction in VEGF-R2 surface expression, ανβ5 integrin expression, endothelial cell tube formation or haptotaxis in the presence of said compound as compared with VEGF-R2 surface expression, ανβ5 integrin expression, endothelial cell tube formation or haptotaxis in the absence of said compound, identifies said compound as a compound that inhibits angiogenesis.
9. The method of claim 8 , wherein the compound is an antibody.
10. The method of claim 8 , wherein the compound is an antisense molecule.
11. The method of claim 8 , wherein the compound is an RNAi molecule.
12. The method of claim 8 , wherein the compound is a small organic molecule.
13. The method of claim 8 , further comprising measuring the USP37 polypeptide ubiquitin hydrolase activity in vitro in the presence of said compound.
14. The method of claim 1 , wherein the USP37 polypeptide is encoded by the nucleotide sequence of SEQ ID NO:22.
15. The method of claim 8 , wherein the USP37 polypeptide is encoded by the nucleotide sequence of SEQ ID NO:22.
16. The method of claim 1 , wherein the angiogenesis phenotype is determined by measuring VEGF-R2 surface expression.
17. The method of claim 8 , wherein the angiogenesis phenotype is determined by measuring VEGF-R2 surface expression.
18. The method of claim 1 , wherein the angiogenesis phenotype is determined by measuring ανβ5 integrin expression.
19. The method of claim 1 , wherein the angiogenesis phenotype is determined by measuring endothelial cell tube formation.
20. The method of claim 1 , wherein the angiogenesis phenotype is determined by measuring haptotaxis.
21. The method of claim 8 , wherein the angiogenesis phenotype is determined by measuring ανβ5 integrin expression.
22. The method of claim 8 , wherein the angiogenesis phenotype is determined by measuring endothelial cell tube formation.
23. The method of claim 8 , wherein the angiogenesis phenotype is determined by measuring haptotaxis.